[go: up one dir, main page]

TR200200461T2 - Alfa-Lipoik asit veya türevlerinin uygulanmasıyla migren tedavisi - Google Patents

Alfa-Lipoik asit veya türevlerinin uygulanmasıyla migren tedavisi

Info

Publication number
TR200200461T2
TR200200461T2 TR2002/00461T TR200200461T TR200200461T2 TR 200200461 T2 TR200200461 T2 TR 200200461T2 TR 2002/00461 T TR2002/00461 T TR 2002/00461T TR 200200461 T TR200200461 T TR 200200461T TR 200200461 T2 TR200200461 T2 TR 200200461T2
Authority
TR
Turkey
Prior art keywords
lipoic acid
alpha
derivatives
application
migraine treatment
Prior art date
Application number
TR2002/00461T
Other languages
English (en)
Inventor
Schoenen Jean
Wessel Klaus
Peukert Manfred
Lobisch Michael
Borbe Harald
Engel Jurgen
Original Assignee
Viatris Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viatris Gmbh & Co. Kg filed Critical Viatris Gmbh & Co. Kg
Publication of TR200200461T2 publication Critical patent/TR200200461T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Bulus, migrenin önlenmesinde ya da migrenin akut ya da kronik tedavisinde aktif içerik olarak, azaltilmis ya da oksitlenmis formda, rasemik alfa-lipoik asit ya da onun enantiomerlerinin ya da farmasötik olarak kabul edilebilir tuzlari, amidleri, esterleri ya da tiyoesterlerinin kullanimi ile ilgilidir.
TR2002/00461T 1999-08-30 2000-08-26 Alfa-Lipoik asit veya türevlerinin uygulanmasıyla migren tedavisi TR200200461T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19941217A DE19941217A1 (de) 1999-08-30 1999-08-30 Behandlung der Migräne durch Verabreichung von alpha-Liponsäure oder Derivaten derselben

Publications (1)

Publication Number Publication Date
TR200200461T2 true TR200200461T2 (tr) 2002-08-21

Family

ID=7920152

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/00461T TR200200461T2 (tr) 1999-08-30 2000-08-26 Alfa-Lipoik asit veya türevlerinin uygulanmasıyla migren tedavisi

Country Status (31)

Country Link
US (1) US6251935B1 (tr)
EP (1) EP1207878B1 (tr)
JP (1) JP4773015B2 (tr)
KR (1) KR100624215B1 (tr)
CN (1) CN1170535C (tr)
AT (1) ATE232725T1 (tr)
AU (1) AU781505B2 (tr)
BG (1) BG65735B1 (tr)
BR (1) BR0013651A (tr)
CA (1) CA2382548C (tr)
CZ (1) CZ301789B6 (tr)
DE (2) DE19941217A1 (tr)
DK (1) DK1207878T3 (tr)
EE (1) EE04869B1 (tr)
ES (1) ES2190985T3 (tr)
HR (1) HRP20020168A2 (tr)
HU (1) HU229603B1 (tr)
IL (2) IL148068A0 (tr)
IS (1) IS2214B (tr)
MX (1) MXPA02002246A (tr)
NO (1) NO328692B1 (tr)
NZ (1) NZ517276A (tr)
PL (1) PL200928B1 (tr)
PT (1) PT1207878E (tr)
RS (1) RS50139B (tr)
RU (1) RU2232577C2 (tr)
SK (1) SK286260B6 (tr)
TR (1) TR200200461T2 (tr)
UA (1) UA71031C2 (tr)
WO (1) WO2001015693A2 (tr)
ZA (1) ZA200201637B (tr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000031060A1 (en) * 1998-11-25 2000-06-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Scavenger compounds
US7030154B2 (en) 2002-06-07 2006-04-18 Juvenon, Inc. Stability of lipoic acid
US20050065094A1 (en) 2003-09-05 2005-03-24 Boehringer Ingelheim International Gmbh Use of telmisartan for the prevention and treatment of vascular headache
US20050282879A1 (en) * 2004-06-17 2005-12-22 Foad Salehani Methods and composition for treatment of migraine and symptoms thereof
US20090054513A1 (en) * 2007-08-22 2009-02-26 Response Scientific, Inc. Method of managing blood glucose levels, insulin levels and/or insulin receptor functionality in individuals with diabetes, polycystic ovarian syndrome and/or alzheimer's disease
US7943163B2 (en) 2007-08-22 2011-05-17 Response Scientific, Inc. Medical food or nutritional supplement, method of manufacturing same, and method of managing diabetes
RU2424803C2 (ru) * 2008-04-07 2011-07-27 Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии имени В.В. Закусова РАМН (НИИ фармакологии имени В.В.Закусова РАМН) Фармацевтическая композиция с противомигреневым действием (варианты)
KR101493125B1 (ko) 2008-11-24 2015-02-12 세다르스-신나이 메디칼 센터 항산화성 캠토테신 유도체 및 이들의 항산화성 항종양성 나노구체
MX2011012134A (es) 2009-05-15 2012-02-08 Redx Pharma Ltd Derivados de farmaco de oxido-reduccion.
KR100935554B1 (ko) 2009-06-24 2010-01-07 주식회사 셀트리온제약 피페라진 다이티옥트산염 및 이를 포함하는 약제학적 조성물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU620265A1 (ru) * 1977-02-21 1978-08-25 Центральный Ордена Трудового Красного Знамени Научно-Исследовательский Институт Курортологии И Физиотерапии Способ лечени атеросклероза сосудов головного мозга и гипертонической болезни
DE58902094D1 (de) * 1988-01-28 1992-10-01 Koeltringer Peter Kombinationspraeparat zur behandlung von nervenzell-und nervenfasererkrankungen und verletzungen.
FI895821A7 (fi) * 1988-12-07 1990-06-08 The Wellcome Foundation Ltd Farmaseuttisesti aktivisia CNS-yhdisteitä
CA2029596C (en) * 1989-11-09 2000-05-23 Heinz Ulrich Medicaments containing r-a-lipoic acid
DE4218572A1 (de) * 1992-06-05 1993-12-09 Asta Medica Ag Synergistische Kombination von Arzneimitteln enthaltend als Wirkstoff alpha-Liponsäure, Dihydroliponsäure, deren Metaboliten sowie die oxidierten und reduzierten Enantiomere der alpha-Liponsäure wie die R-alpha-Liponsäure oder S-alpha-Liponsäure sowie Metaboliten der alpha-Liponsäure mit den Vitaminen A, B1-6, B12, C und E
US5569670A (en) * 1992-06-05 1996-10-29 Asta Medica Aktiengesellschaft Combination medications containing alpha-lipoic acid and related
EP0604641B1 (en) * 1992-06-30 2002-03-20 SHAPIRO, Howard, K. Use of a combination containing an amine or amine-related derivative of benzoic acid and an amino-polysaccharide in the manufacture of a medicament for the treatment of inflammatory diseases
DE4327426A1 (de) * 1993-08-14 1995-02-16 F H Erdaussiebung Gmbh Anbaugerät zum Sieben und Verfüllen von Erdmaterialien
DE4327462A1 (de) * 1993-08-16 1995-02-23 Carl Heinrich Dr Weischer Neue N-Acetyl-p-Aminophenol-Derivate zur Bekämpfung von Schmerzzuständen
DE4331168A1 (de) * 1993-09-14 1995-03-16 Carl Heinrich Dr Weischer Kombination von N-Acetyl-p-Aminophenol mit schwefelenthaltenden Carbonsäuren, wie z. B. alpha-Liponsäure und deren Derivate, zur Bekämpfung von Schmerzzuständen
EP0855396A1 (en) * 1997-01-22 1998-07-29 ASTA Medica Aktiengesellschaft Thioctic acid metabolites and methods of use thereof
IL123887A0 (en) * 1997-04-02 1998-10-30 Sankyo Co Dithiolan derivatives their use and pharmaceutical compositions containing the same
WO1999006040A1 (en) * 1997-08-04 1999-02-11 Berry Christopher J Method of treating disease using a tocotrienol and alpha-lipoic acid or derivatives or an ester thereof
GB2333757B (en) * 1998-02-03 2001-06-27 Cheung Kwok Chung Sliding platform
CA2327095A1 (en) * 1998-04-02 1999-10-14 Avicena Group, Inc. Compositions containing a combination of a creatine compound and a second agent
AR042572A1 (es) * 1999-04-02 2005-06-29 Sod Conseils Rech Applic Derivados de acido lipoico, procedimiento para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y utilizacion de dichos derivados para la preparacion de los referidos medicamentos

Also Published As

Publication number Publication date
DE50001301D1 (de) 2003-03-27
KR20020060168A (ko) 2002-07-16
JP4773015B2 (ja) 2011-09-14
RS50139B (sr) 2009-03-25
NO328692B1 (no) 2010-04-26
SK286260B6 (sk) 2008-06-06
NO20020917L (no) 2002-02-25
HU229603B1 (en) 2014-02-28
JP2003508438A (ja) 2003-03-04
CZ301789B6 (cs) 2010-06-23
EE200200098A (et) 2003-04-15
BR0013651A (pt) 2002-05-07
RU2232577C2 (ru) 2004-07-20
CA2382548A1 (en) 2001-03-08
US6251935B1 (en) 2001-06-26
CA2382548C (en) 2007-07-03
UA71031C2 (uk) 2004-11-15
BG106407A (en) 2002-10-31
PL200928B1 (pl) 2009-02-27
IL148068A (en) 2007-06-03
CN1371280A (zh) 2002-09-25
HUP0203025A3 (en) 2004-12-28
ATE232725T1 (de) 2003-03-15
DE19941217A1 (de) 2001-03-15
EE04869B1 (et) 2007-08-15
NZ517276A (en) 2004-06-25
PL352741A1 (en) 2003-09-08
SK2902002A3 (en) 2002-09-10
ES2190985T3 (es) 2003-09-01
HK1046637A1 (en) 2003-01-24
EP1207878A2 (de) 2002-05-29
MXPA02002246A (es) 2003-08-20
BG65735B1 (bg) 2009-09-30
KR100624215B1 (ko) 2006-09-18
IS6284A (is) 2002-02-26
CZ2002655A3 (cs) 2002-07-17
WO2001015693A3 (de) 2001-12-20
IS2214B (is) 2007-03-15
DK1207878T3 (da) 2003-06-16
PT1207878E (pt) 2003-07-31
HUP0203025A2 (hu) 2002-12-28
AU7279900A (en) 2001-03-26
WO2001015693A2 (de) 2001-03-08
CN1170535C (zh) 2004-10-13
AU781505B2 (en) 2005-05-26
YU15002A (sh) 2005-03-15
ZA200201637B (en) 2003-01-29
EP1207878B1 (de) 2003-02-19
IL148068A0 (en) 2002-09-12
HRP20020168A2 (en) 2003-06-30
NO20020917D0 (no) 2002-02-25

Similar Documents

Publication Publication Date Title
MY130441A (en) Solutions containing epinastin
DK1178958T3 (da) N-cyanomethylamider som proteaseinhibitorer
DK1194425T3 (da) Substituerede benzimidazoler
DK0991407T3 (da) Stabilisering af syresensitive benzimidazoler med amino/cyclodextrin-kombinationer
UY26082A1 (es) Derivados de 1,4-diazabiciclo [3.2.2] nonan-4-carboxilato y -carboxamidas, su preparacion y su aplicacion en terapeutica
TR199802060T2 (tr) Aminoisokinolinler ve aminopiridin türevlerinin iltihap önleyiciler olarak kullanimi.
TR200200461T2 (tr) Alfa-Lipoik asit veya türevlerinin uygulanmasıyla migren tedavisi
MEP24008A (en) Esters of l-carnitine or alkanoyl l-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds
ATE295165T1 (de) Mittel zur adjuvanten therapie von demenzen enthaltend alpha-liponsäure
TR199800386T1 (tr) Analjezik ajan olarak kullanilan optik aktiviteye sahip fenil pirimidin türevleri.
SE0002211D0 (sv) Methods and compositions for prevention of myopia
WO2002009717A1 (en) Erectile dysfunction remedies containing prostaglandin derivatives as the active ingredient
DK1232173T3 (da) Nye fusidinsyrederivater